Lots has happened since my last video! Today I talk about the updates from ASH 2018, with a focus on BLUE and GBT. I also talk about FATE, MRNA, and the companies making bispecifics. This is not investment advice, but for information only.
“We are extremely disappointed with the FDA’s decision”, writes the Ionis Pharma press release in describing the Complete Response Letter (CRL) they received regarding their latest medicine, WAYLIVRA. They continue, “we feel strongly that WAYLIVRA demonstrates a favorable benefit/risk profile in people with FCS as was reflected in the positive outcome from our Advisory Committee […]